Stifel Financial Corp Buys 91,881 Shares of Harrow, Inc. (NASDAQ:HROW)

Stifel Financial Corp grew its stake in shares of Harrow, Inc. (NASDAQ:HROWFree Report) by 27.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 431,973 shares of the company’s stock after acquiring an additional 91,881 shares during the quarter. Stifel Financial Corp owned about 1.23% of Harrow worth $4,838,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of HROW. Braidwell LP increased its holdings in Harrow by 24.5% in the 3rd quarter. Braidwell LP now owns 1,808,684 shares of the company’s stock worth $25,991,000 after buying an additional 356,146 shares in the last quarter. Vanguard Group Inc. increased its holdings in Harrow by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,759,879 shares of the company’s stock worth $25,289,000 after buying an additional 95,389 shares in the last quarter. Paradigm Capital Management Inc. NY bought a new stake in Harrow in the 3rd quarter worth about $5,655,000. Franklin Resources Inc. increased its holdings in Harrow by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 294,221 shares of the company’s stock worth $3,295,000 after buying an additional 64,252 shares in the last quarter. Finally, Westside Investment Management Inc. increased its holdings in Harrow by 33.5% in the 4th quarter. Westside Investment Management Inc. now owns 212,314 shares of the company’s stock worth $2,378,000 after buying an additional 53,295 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Harrow

In other Harrow news, CEO Mark L. Baum acquired 9,000 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were bought at an average price of $11.59 per share, with a total value of $104,310.00. Following the transaction, the chief executive officer now directly owns 2,137,525 shares of the company’s stock, valued at approximately $24,773,914.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Opaleye Management Inc. bought 50,600 shares of the stock in a transaction on Wednesday, March 20th. The stock was acquired at an average cost of $9.65 per share, for a total transaction of $488,290.00. Following the acquisition, the insider now owns 3,695,600 shares of the company’s stock, valued at $35,662,540. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Mark L. Baum bought 9,000 shares of the stock in a transaction on Friday, March 22nd. The stock was purchased at an average price of $11.59 per share, with a total value of $104,310.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The disclosure for this purchase can be found here. Insiders have acquired 170,715 shares of company stock valued at $1,864,011 in the last quarter. 13.67% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HROW has been the subject of several research analyst reports. B. Riley reiterated a “buy” rating and issued a $29.00 price objective (up from $26.00) on shares of Harrow in a report on Wednesday, May 15th. Lake Street Capital lifted their price objective on Harrow from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, June 3rd. Finally, Craig Hallum boosted their price target on Harrow from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th.

Get Our Latest Analysis on Harrow

Harrow Stock Up 1.2 %

NASDAQ HROW opened at $18.17 on Monday. The stock has a market cap of $642.85 million, a PE ratio of -19.97 and a beta of 0.88. The company has a current ratio of 3.00, a quick ratio of 2.75 and a debt-to-equity ratio of 3.06. The stock’s 50 day moving average is $13.74 and its 200 day moving average is $11.62. Harrow, Inc. has a 12 month low of $7.60 and a 12 month high of $22.63.

Harrow (NASDAQ:HROWGet Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03). The company had revenue of $34.59 million for the quarter, compared to the consensus estimate of $34.37 million. Harrow had a negative net margin of 22.59% and a negative return on equity of 39.82%. Research analysts predict that Harrow, Inc. will post -0.51 EPS for the current fiscal year.

Harrow Company Profile

(Free Report)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Featured Articles

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROWFree Report).

Institutional Ownership by Quarter for Harrow (NASDAQ:HROW)

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.